Get the Stockscreener App
39.61
0.05%
0.02
After Hours:
39.60
-0.010
-0.03%
Centessa Pharmaceuticals Plc Adr stock is traded at $39.61, with a volume of 3.59M.
It is up +0.05% in the last 24 hours and up +50.44% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
See More
Previous Close:
$39.59
Open:
$39.5
24h Volume:
3.59M
Relative Volume:
1.46
Market Cap:
$6.13B
Revenue:
$15.06M
Net Income/Loss:
$-197.82M
P/E Ratio:
-27.19
EPS:
-1.4568
Net Cash Flow:
$-194.64M
1W Performance:
+0.20%
1M Performance:
+50.44%
6M Performance:
+75.50%
1Y Performance:
+231.74%
1-Day Range:
$39.38
$39.63
1-Week Range:
$39.16
$39.80
52-Week Range:
$10.95
$40.26
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
39.61 | 6.12B | 15.06M | -197.82M | -194.64M | -1.4568 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Dec-10-25 | Resumed | Oppenheimer | Outperform |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Aug-29-25 | Resumed | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal - MSN
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Finviz
Looks Like M&A Week in 3 Different Sectors - The Motley Fool
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Free cash flow per share of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
This Akamai Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – What’s Next? - Defense World
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA) - Sahm
Centessa Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CNTA) - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal - Yahoo Finance
JPMorgan Chase & Co. Sells 186,539 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
SG Americas Securities LLC Buys 240,039 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals stock hits all-time high at 40.03 USD By Investing.com - Investing.com South Africa
Weight-Loss Drug Giant Eli Lilly Bets Big Again. Spending $7.8 Billion to Acquire Centessa, Is Now a Good Time to Buy Eli Lilly? - TradingKey
Lilly (NYSE: LLY) buying Centessa (NASDAQ: CNTA) for $38 plus CVR - Stock Titan
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout - Finviz
Gold Gains Over 1%; FactSet Research Raises FY2026 OutlookApellis Pharmaceuticals (NASDAQ:APLS), Cente - Benzinga
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders - Barchart.com
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? - Finviz
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 52-Week HighTime to Buy? - MarketBeat
Eli Lilly (LLY) Stock Rises as Company Agrees to Buy Centessa in $6.3 Billion Sleep Drug Deal - MEXC Exchange
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High - Benzinga
Centessa Pharmaceuticals stock hits all-time high at 40.03 USD - Investing.com
AASTOCKS Financial NewsCentessa Pharmaceuticals plc (CNTA) - AASTOCKS.com
CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders - ChartMill
Karen Anderson Sells 41,076 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - Defense World
Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 7%Here's Why - MarketBeat
41,076 ADS proposed for sale by affiliate (NASDAQ: CNTA) — Form 144 - Stock Titan
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 64,768 Shares - MarketBeat
Karen Anderson Sells 10,043 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - MarketBeat
Karen M. Anderson sells ADRs; CNTA (NASDAQ: CNTA) Form 144 notice - Stock Titan
Cinctive Capital Management LP Purchases New Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
[144] Centessa Pharmaceuticals plc SEC Filing - Stock Titan
First Light Asset Management LLC Sells 657,595 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Holdings Cut by Commodore Capital LP - MarketBeat
Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start - Yahoo Finance
Avoro Capital Advisors LLC Buys 5,808,080 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Gregory Weinhoff Sells 73,196 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 120,029 Shares - MarketBeat
CNTA (NASDAQ: CNTA) insider files Form 144 to sell 120,029 ADRs valued $3.10M - Stock Titan
Capital World Investors Has $16.61 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by American Century Companies Inc. - Defense World
American Century Companies Inc. Has $27.08 Million Stock Position in BJ’s Restaurants, Inc. $BJRI - Defense World
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference - Yahoo Finance
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):